Amendment to “Standard Processing Licence” to Allow for Sales”

Ayurcann Inc. News Release
FOR IMMEDIATE RELEASE, January 14, 2020

Picketing, Ontario, January 14, 2020 – Ayurcann Inc. d.b.a XTRX Solutions Inc. (“Ayurcann”) has been granted an amendment to standard processing licence from Health Canada (the “Amended License”).

This licence will allow Ayurcann to have direct access to the recreational market. The Company can sell extracts, edibles and topical products to provincial cannabis boards and create new direct relationships to list new product SKUs and open additional revenue streams to produce and white label new finished cannabis products for the licensed producers and brands across Canada.
On November 24, 2020, the Company entered into a definitive business combination agreement with Canada Coal to affect a reverse takeover of the Company, the details of which are disclosed in the Company’s press release dated November 25, 2020.
Description of Ayurcann and its Business
Ayurcann is a leading provider of customized post-harvest outsourcing solutions to licensed cannabis producers. Ayurcann concentrates on the post-harvest requirements of licensed cannabis producers and other brands looking to enter the cannabis market. Ayurcann offers end-to-end full outsourcing solutions including extraction, refinement, formulation, packaging, fulfillment and distribution.

Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release. Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the future plans, objectives or goals, including words to the effect that the company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.

Subscribe to our newsletter to stay up-to-date with Ayurcann.